Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-150) | Dec 05, 2017 |
New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8512717 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(3 years from now) | |
US9192571 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-630) | Oct 29, 2013 |
New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
New Indication(I-638) | May 05, 2014 |
New Indication(I-650) | Apr 26, 2015 |
New Indication(I-655) | Jul 20, 2015 |
Pediatric Exclusivity(PED) | Apr 29, 2018 |
Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
New Indication(I-724) | Feb 26, 2019 |
Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of patients with progressive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8729019 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 27, 2020 |
M(M-61) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 10, 2019 |
New Dosing Schedule(D-194) | Oct 04, 2027 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: NA
Dosage: GEL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7582727 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) | |
US7598343 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 18, 2016 |
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(3 years from now) | |
US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(3 years from now) | |
US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-150) | Aug 27, 2018 |
New Indication(I-715) | Aug 27, 2018 |
New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8226975 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SUSPENSION, LIPOSOMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 27, 2020 |
New Patient Population(NPP) | Jul 09, 2024 |
New Strength(NS) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 20, 2017 |
New Patient Population(NPP) | May 17, 2021 |
New Strength(NS) | May 17, 2021 |
M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 31, 2012 |
M(M-129) | Aug 30, 2016 |
New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071073 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 31, 2012 |
M(M-129) | Aug 30, 2016 |
New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(2 years from now) | |
US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Oct 08, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(3 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of venous thrombosis
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 30, 2018 |
New Indication(I-708) | Apr 30, 2018 |
New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
M(M-202) | May 15, 2020 |
New Patient Population(NPP) | May 13, 2026 |
New Strength(NS) | May 13, 2026 |
Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(2 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 27, 2015 |
M(M-162) | Sep 24, 2018 |
M(M-212) | Oct 20, 2020 |
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 20, 2020 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(2 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(3 years from now) | |
US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
US8758292 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(3 years from now) | |
US8216180 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(3 years from now) | |
US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US8439864 (Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(3 years from now) | |
US9320853 (Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(3 years from now) | |
US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-187) | Sep 02, 2019 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-882) | Dec 17, 2024 |
New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
Orphan Drug Exclusivity(ODE) | Apr 06, 2018 |
Orphan Drug Exclusivity(ODE-9) | Apr 06, 2018 |
Drugs and Companies using VANDETANIB ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 06 April, 2011
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(3 years from now) | |
US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(3 years from now) | |
US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(3 years from now) | |
US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(3 years from now) | |
US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(3 years from now) | |
US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-603) | Jul 30, 2012 |
Orphan Drug Exclusivity(ODE) | Jul 29, 2016 |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: A method for treatment of gout flares during prophylaxis; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of treating gout flares; Method of us...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(3 years from now) | |
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
ODE*(ODE*) | Mar 06, 2022 |
Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
New Patient Population(NPP) | Dec 08, 2026 |
Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Mar 29, 2020 |
M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocardi...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-154) | Jan 20, 2019 |
New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
New Patient Population(NPP) | Jul 22, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose regimen of dalbavancin
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 30, 2012 |
Pediatric Exclusivity(PED) | Jul 30, 2012 |
New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(2 years from now) | |
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(3 years from now) |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Mar 17, 2013 |
RTO(RTO) | Jul 08, 2019 |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of acne
Dosage: LOTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8859510 (Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) | |
US7378508 (Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(3 years from now) | |
US7863249 (Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
New Product(NP) | Jan 24, 2023 |
New Patient Population(NPP) | Jan 24, 2023 |
Pediatric Exclusivity(PED) | Jul 24, 2023 |
Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
NCE-1 date: 24 July, 2022
Market Authorisation Date: 27 May, 2011
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7608616 | GALT PHARMS | Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia |
Jun, 2028
(3 years from now) |
Drugs and Companies using QUAZEPAM ingredient
Market Authorisation Date: 26 February, 1987
Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-136) | Apr 11, 2016 |
New Strength(NS) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Apr 08, 2022 |
New Indication(I-839) | Aug 06, 2023 |
New Patient Population(NPP) | Apr 05, 2027 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(3 years from now) |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(3 years from now) | |
US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(3 years from now) |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Dec 20, 2014 |
New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9844510 | LAB HRA PHARMA | Ulipristal acetate tablets |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11110081 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
US11123331 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
US11419823 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
US9549918 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
US12083103 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
US10166190 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
US10864199 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
US8685998 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(3 years from now) | |
US8644239 | VELOXIS PHARMS INC | Method and apparatus for allocating and processing sequences in communication system |
Aug, 2028
(3 years from now) | |
US8664239 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11357859 | TAKEDA PHARMS USA | Compositions for the treatment of gastrointestinal inflammation |
Nov, 2028
(3 years from now) | |
US10293052 | TAKEDA PHARMS USA | Compositions for the treatment of gastrointestinal inflammation |
Nov, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 09, 2027 |
Orphan Drug Exclusivity(ODE-466) | Feb 09, 2031 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 09 February, 2024
Treatment: Treatment of eosinophilic esophagitis
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
New Patient Population(NPP) | Mar 19, 2023 |
New Strength(NS) | Mar 19, 2023 |
M(M-264) | Jul 14, 2023 |
M(M-277) | Apr 27, 2025 |
Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7888364 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Nov, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9278961 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 30, 2017 |
Drugs and Companies using VISMODEGIB ingredient
NCE-1 date: 31 January, 2016
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat cancer in a mammal
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(3 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(3 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Increasing production of functional dystrophin protein in dmd patients having a mutation of the dmd...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
US8221786 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US8716251 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-157) | Mar 11, 2018 |
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-212) | Oct 20, 2020 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Indication(I-834) | May 05, 2023 |
New Indication(I-857) | Apr 30, 2024 |
M(M-298) | May 08, 2026 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 23, 2020 |
Orphan Drug Exclusivity(ODE) | Feb 23, 2022 |
Orphan Drug Exclusivity(ODE-89) | Feb 23, 2022 |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
NCE-1 date: 23 February, 2019
Market Authorisation Date: 23 February, 2015
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(3 years from now) | |
US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(3 years from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7799331 | TARO | Oral suspension of prednisolone acetate |
Oct, 2028
(3 years from now) |
Drugs and Companies using PREDNISOLONE ACETATE ingredient
Market Authorisation Date: 17 January, 2008
Treatment: Treatment of allergic reactions
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8347879 | HALEON US HOLDINGS | Fluid dispensing device |
Jul, 2028
(3 years from now) | |
US8147461 | HALEON US HOLDINGS | Fluid dispensing device |
Oct, 2028
(3 years from now) |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8226929 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac imaging
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7829574 | TAKEDA PHARMS USA | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
May, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8212033 | TAKEDA PHARMS USA | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 08, 2028 |
Drugs and Companies using FRUQUINTINIB ingredient
NCE-1 date: 09 November, 2027
Market Authorisation Date: 08 November, 2023
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jan 30, 2018 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
M(M-258) | Jul 03, 2022 |
M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8389578 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Jan, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-769) | Aug 24, 2020 |
New Product(NP) | Aug 24, 2020 |
Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-153) | Nov 12, 2018 |
New Indication(I-718) | Nov 12, 2018 |
New Indication(I-719) | Nov 12, 2018 |
New Indication(I-720) | Nov 12, 2018 |
New Dosing Schedule(D-158) | Feb 12, 2019 |
New Dosing Schedule(D-159) | Feb 12, 2019 |
New Dosing Schedule(D-160) | Feb 12, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
New Patient Population(NPP) | Apr 07, 2020 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
ODE*(ODE*) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
Pediatric Exclusivity(PED) | Oct 07, 2024 |
Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8987262 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(3 years from now) | |
US8338489 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 14, 2017 |
Orphan Drug Exclusivity(ODE) | Mar 14, 2021 |
Orphan Drug Exclusivity(ODE-62) | Mar 14, 2021 |
Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 March, 2014
Treatment: Method to treat infantile hemangioma; Method to treat hemangioma.
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-680) | Feb 12, 2017 |
New Indication(I-689) | Jul 28, 2017 |
New Indication(I-702) | Jan 29, 2018 |
New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
New Indication(I-729) | Mar 04, 2019 |
New Dosing Schedule(D-165) | May 06, 2019 |
New Indication(I-736) | May 06, 2019 |
New Indication(I-737) | May 06, 2019 |
New Indication(I-741) | Jan 18, 2020 |
New Indication(I-753) | Aug 02, 2020 |
Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
New Dosing Schedule(D-176) | Aug 24, 2021 |
M(M-236) | Jan 25, 2022 |
Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
ODE*(ODE*) | Aug 02, 2024 |
Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
M(M-14) | Aug 24, 2025 |
New Product(NP) | Aug 24, 2025 |
New Patient Population(NPP) | Aug 24, 2025 |
Pediatric Exclusivity(PED) | Feb 24, 2026 |
Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: CAPSULE; SUSPENSION; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8161968 | GLAXO GRP ENGLAND | Medicament dispenser |
Feb, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
M(M-172) | Feb 24, 2019 |
M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 25, 2016 |
New Strength(NS) | Apr 28, 2024 |
New Patient Population(NPP) | Nov 19, 2024 |
New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(3 years from now) | |
US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8138199 | BRISTOL-MYERS | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: NA
Dosage: INSERT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
New Dosage Form(NDF) | Dec 20, 2016 |
New Patient Population(NPP) | Nov 22, 2020 |
M(M-114) | Mar 28, 2015 |
New Dosing Schedule(D-167) | May 26, 2020 |
Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
New Indication(I-699) | Dec 04, 2017 |
Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
New Indication(I-799) | May 24, 2022 |
New Indication(I-872) | Sep 22, 2024 |
M(M-285) | Dec 19, 2025 |
Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-ess...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8414921 | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
M(M-244) | Aug 12, 2022 |
M(M-187) | Dec 04, 2023 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-159) | Jun 26, 2018 |
M(M-160) | Jun 26, 2018 |
M(M-161) | Jun 26, 2018 |
M(M-174) | Mar 18, 2019 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
New Indication(I-869) | Aug 18, 2024 |
M(M-82) | Feb 24, 2025 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
New Patient Population(NPP) | Jun 20, 2026 |
New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) | |
US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) | |
US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) | |
US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) | |
US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) | |
US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toe...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, |